XIENCE Sierra: Slim, Strong, Precise

Specifically Designed for the Treatment of Complex Patients

To provide effective treatment in complex lesions during percutaneous coronary intervention (PCI), a stent must be slim so it can get to the lesion, strong to effectively treat challenging vessels, while also offering percise stent placement and deployment. XIENCE Sierra has all three characteristics.

SLIM

Lowest crossing profile of any
drug-eluting stent (DES) on the market1

STRONG

Greatest longitudinal strength of any
DES, best stent retention on the
market, and robust radial strength1

PRECISE

100% accurate mid-market placement
with 0% shortening for precise stent
placement2

Slim: Lowest Crossing Profile of Any DES3

XIENCE Sierra's Slim Flex Technology is a key innovation: it enables XIENCE Sierra to have the lowest crossing profile of any drug-eluting stent3 on the U.S. market while enhancing the maximum expansion capability.4 This makes it an ideal choice:

  • For tight, calcified lesions
  • In small, tapered vessels like those in patients with diabetes
  • For patients best treated via radial access

SLIM FLEX TECHNOLOGY

Slim: Lowest Crossing Profile of Any DES3

XIENCE Sierra's Slim Flex Technology is a key innovation: it enables XIENCE Sierra to have the lowest crossing profile of any drug-eluting stent3 on the U.S. market while enhancing the maximum expansion capability.4 This makes it an ideal choice:

  • For tight, calcified lesions
  • In small, tapered vessels like those in patients with diabetes
  • For patients best treated via radial access

SLIM FLEX TECHNOLOGY

Strong: Longitudinal Strength, Retention and Radial Strength

GREATEST LONGITUDINAL STRENGTH5

XIENCE Sierra has the greatest longitudinal strength of any drug-eluting stent on the market.5 When tested for stent compression (shortening of the stent under a 50gf load), XIENCE Sierra demonstrates:

Strong: Longitudinal Strength, Retention and Radial Strength

GREATEST LONGITUDINAL STRENGTH5

XIENCE Sierra has the greatest longitudinal strength of any drug-eluting stent on the market.5 When tested for stent compression (shortening of the stent under a 50gf load), XIENCE Sierra demonstrates:

Lower values indicate stronger performance.

BEST STENT RETENTION ON THE MARKET6

In addition, XIENCE Sierra exhibits market-leading stent retention, which is critical in challenging anatomy. In testing stent retention data6 show that XIENCE Sierra is:

BEST STENT RETENTION ON THE MARKET6

In addition, XIENCE Sierra exhibits market-leading stent retention, which is critical in challenging anatomy. In testing stent retention data6 show that XIENCE Sierra is:

ROBUST RADIAL STRENGTH6

XIENCE Sierra radial strength is also robust in comparison to competitors.6

Precise: For Precision Stent Placement

Zero Shortening Upon Deployment

XIENCE Sierra demonstrates 0% stent shortening upon deployment at maximum expansion. This enables the precision in stent placement that is especially cirtical in complex lesions.7

100% ACCURATE STENT MARKER PLACEMENT

A key feature for any stent is accurate delivery to the target lesion, and XIENCE Sierra offers 100% accurate stent mid-marker placement so the stent can be precisely aligned with the lesion.8

100% ACCURATE STENT MARKER PLACEMENT

A key feature for any stent is accurate delivery to the target lesion, and XIENCE Sierra offers 100% accurate stent mid-marker placement so the stent can be precisely aligned with the lesion.8

AP2945972-WBU Rev. A

  1. Data on file at Abbott and refers to 3.0 mm diameter and 18-20 mm lengths. Comparative claim refers to major drug-eluting stent manufacturers in U.S. market. Crossing profile refers to 3.0 mm diameter size. Longitudinal strength refers to 3.0 mm diameter and 28-30 mm lengths.
  2. Refers to 4.0 mm diameter expanded to 5.5 mm.
  3. Comparative claim refers to major drug-eluting stent manufacturers in U.S. market, including Medinol. Crossing profile refers to 3.0 mm diameter and 18-20 mm lengths.
  4. All references to maximum expansion refer to expansion through post-dilatation.
  5. Comparative claim refers to major drug-eluting stent manufacturers in U.S. market, as well as BIOTRONIK. Orsiro™ is not available nor for sale in the U.S. as of April 2018.  Longitudinal strength refers to 3.0 mm diameter and 28-30 mm lengths.
  6. Test performed by and data on file at Abbott. Data refers to 3.0 mm diameter and 18-20 mm lengths.
  7. Data on file at Abbott. Orsiro™ is not available or for sale in the United States as of April 2018. Refers to 4.0 mm diameter at 5.5 mm maximum expansion.
  8. Test performed by and data on file at Abbott. Orsiro™ is not available or for sale in the United States as of April 2018. Data refers to 3.0 mm diameter and 18-20 mm lengths.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?
Important safety information